Skip To Main Content
Venu Kumar Vemula on Muck Rack

Venu Kumar Vemula

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Venu Kumar

Contact Venu Kumar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Extensive physicochemical and biological characterization of BP02, a trastuzumab biosimilar, and comparative assessment with Herceptin

|
By Sanjeeva Metikala, Yash Patel, Naga Satish, Raghu Chitta, Maheswara Rao Bogadi, Venu Kumar Vemula, D. R. Yashwanth Kumar, Nagarjuna Reddy Vuchuru, Kambagiri Swamy Kayala, Pujitha Yarlagadda, Srilalitha Kuruganti, Disha Dadke
| Nature Verified
Abstract Trastuzumab is an IgG1 monoclonal antibody that targets the extracellular HER2 domain on HER2 + cancer cells. CuraTeQ biologics has developed a trastuzumab biosimilar, code named BP02, aimed at treating early and metastatic breast cancer and metastatic gastric cancer. This biosimilar has been thoroughly characterized through physicochemical and biological methods in accordance with established guidelines.
Open in Who Shared Issue with article?
See all 1 articles